Syndax Pharmaceuticals Lands $26,600,000 Series B Financing

  • Feed Type
  • Date
    8/27/2013
  • Company Name
    Syndax Pharmaceuticals
  • Mailing Address
    400 Totten Pond Road Waltham, MA 02451
  • Company Description
    Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused biotechnology company that is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens.
  • Website
    http://www.syndax.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $26,600,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Syndax plans to use the proceeds to continue advancement of its late-stage pipeline of epigenetic-based combination therapies for treatment-resistant cancers, including activities in preparation for an NDA-enabling Phase 3 study of entinostat in metastatic breast cancer.
  • M&A Terms
  • Venture Investor
    Domain Associates
  • Venture Investor
    MPM Capital
  • Venture Investor
    Forward Ventures
  • Venture Investor
    RusnanoMedInvest

By posting a comment, you agree to our terms and conditions.